From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases DME Interactive Data Deep Dive

From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases DME Interactive Data Deep Dive is organized by Paradigm Medical Communications, LLC.

Release Date: September 29, 2022
Expiration Date: September 29, 2023

Program Overview:
This engaging infographic activity will take learners on an interactive, multimedia journey through the pivotal phase 3 trials that led to the recent FDA approval of faricimab for the treatment of diabetic macular edema (DME). Because faricimab differs significantly from anti-VEGF, a thorough understanding of key data and contextualization by experts will be crucial in elucidating the role of faricimab and appropriately integrating this novel therapy into clinical practice.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Articulate clinical trial designs of recently available novel therapies that are indicated for the treatment of neovascular retinal diseases
• Summarize safety and efficacy data for recently available novel treatments for neovascular retinal diseases.